MEDICOWL GROUP

HYARELIEF

LINEAR & CROSS-LINKED HYALURONIC ACID



Medicowl Group (Suisse) SA

Les Favresses 7 | CH-1483 Montet | Switzerland
+41 (0)26 424 77 77
contact@medicowl-group.com

Medicowl Group (France) SAS

255 rue du Ruisseau d'Urpont
54170 Fleville (Nancy) | France
+33 (0)3 75 97 07 07 | france@medicowl-group.com

ABOUT MEDICOWL

SWITZERLAND & FRANCE | MEDICAL DISTRIBUTION

Medicowl | group

A partner for healthcare professionals

Medicowl Group is a Swiss medical distribution company operating across several international markets. We specialise in innovative solutions for orthopaedics, sports medicine and regenerative medicine, combining trusted products with reliable service, product training and scientific education.

ORTHOPAEDICS

Products and support for specialist orthopaedic practice.

SPORTS MEDICINE

A portfolio serving healthcare professionals in sports medicine.

REGENERATIVE MEDICINE

Hyaluronic acid and autologous preparation systems.

Medicowl Group (Suisse) SA

Les Favresses 7 | CH-1483 Montet | Switzerland
+41 (0)26 424 77 77
contact@medicowl-group.com

Medicowl Group (France) SAS

255 rue du Ruisseau d'Urpont
54170 Fleville (Nancy) | France
+33 (0)3 75 97 07 07 | france@medicowl-group.com

Hyaluronic acid for intra-articular viscosupplementation

Hyaluronic acid is a natural component of synovial fluid. Its viscoelastic properties contribute to joint lubrication and cushioning.

What is HyaRelief?

A range of sodium-hyaluronate products intended for viscoelastic replenishment or replacement of synovial fluid in joint disorders such as osteoarthritis.

Two formulations

The linear range contains non-cross-linked sodium hyaluronate. HyaRelief Cross contains cross-linked sodium hyaluronate and is presented here in 75 mg and 90 mg strengths.

Professional administration

Delivered into the joint by a healthcare professional trained in intra-articular injection. Product selection and repeat treatment follow clinical assessment and the applicable instructions for use.

Patient assessment

Review ingredient sensitivity and infection at or around the injection site. Discuss expected benefits, adverse effects and follow-up with the clinician. Consult the full instructions for use.

PRODUCTS

HYARELIEF | LINEAR SODIUM HYALURONATE

Seven concentration and volume combinations in pre-filled syringes, for intra-articular viscosupplementation.



20 mg	30 mg	40 mg	48 mg	60 mg	75 mg	90 mg
1.0%	1.5%	2.0%	2.4%	2.4%	2.5%	3.0%
2 mL	2 mL	2 mL	2 mL	2.5 mL	3 mL	3 mL

Intended for viscoelastic replenishment or replacement of synovial fluid in joint disorders such as osteoarthritis. Product choice and the administration schedule follow the applicable instructions for use and clinical assessment.

HYARELIEF LINEAR

75 MG & 90 MG | FORMULATION & REPORTED BENEFITS



75 mg / 3 ml



90 mg / 3 ml

High concentration
High molecular weight
A non-cross-linked option

Biofermentation origin

100% natural hyaluronic acid obtained by biofermentation, with N-acetylglucosamine, a precursor of hyaluronic acid.

High molecular weight

75 mg: 2.1 million Da
90 mg: 2.6 million Da
Reported joint residence time: more than 30 days.

Non-cross-linked formulation

No chemical cross-linking agent (no BDDE). Designed to respect the natural biology and matrix of the joint.

Patient selection

Positioned for first injections, sensitive patients and budget-conscious care, subject to clinical assessment and contraindications.

PRODUCTS

HYARELIEF CROSS | CROSS-LINKED SODIUM HYALURONATE



HyaRelief Cross 2.5%

75 mg / 3 mL

Cross-linked sodium hyaluronate
One sterile, pre-filled 3 mL syringe
For intra-articular administration



HyaRelief Cross 3.0%

90 mg / 3 mL

Cross-linked sodium hyaluronate
One sterile, pre-filled 3 mL syringe
For intra-articular administration

HYARELIEF CROSS

75 MG & 90 MG | FORMULATION & REPORTED BENEFITS



75 mg / 3 ml | 2.5%



90 mg / 3 ml | 3.0%

Composition & molecular weight

Biofermentation-derived hyaluronic acid with N-acetylglucosamine.
75 mg: 2.1 million Da | 90 mg: 2.6 million Da

Controlled cross-linking

Formaldehyde-free formulation, described as free of microcrystals. Cross-linking is intended to increase resistance to enzymatic degradation.

Rheology & residence time

Reported elasticity up to 200 Pa and viscosity up to 127.32 Pa (at 2.5 Hz).
Reported residence: 35-55 days for Cross 90; more than 30 days for Cross 75.

Patient profile

Positioned for active patients and more advanced osteoarthritis, with selection based on clinical assessment.

HYARELIEF AT A GLANCE

REPORTED CHARACTERISTICS | 75 MG & 90 MG FORMULATIONS

Medicowl | group

Characteristic	Linear 75	Linear 90	Cross 75	Cross 90
Structure	Linear	Linear	Cross-linked	Cross-linked
Dose / concentration	75 mg / 3 ml 2.5%	90 mg / 3 ml 3.0%	75 mg / 3 ml 2.5%	90 mg / 3 ml 3.0%
Molecular weight	2.1 million Da	2.6 million Da	2.1 million Da	2.6 million Da
Elasticity at 2.5 Hz	150 Pa	Approx. 175 Pa	150 Pa	200 Pa
Viscosity at 2.5 Hz	95.49 Pa	Approx. 110 Pa	95.49 Pa	127.32 Pa
Joint residence	More than 30 days	Approx. 30-35 days	More than 30 days	35-55 days
Chemistry	Natural HA + N-acetylglucosamine	Natural HA + N-acetylglucosamine	Formaldehyde-free; no microcrystals	Formaldehyde-free; no microcrystals
Positioning	First-line; early to moderate OA	Moderate to advanced OA; volume needs	Cross-linked option; intermediate stages	Advanced OA; active patients

OTHER VISCOSUPPLEMENT OPTIONS

COMPARISON INFORMATION FROM THE SUPPLIED RANGE PRESENTATION

Medicowl | group

Characteristic	Ostenil / Ostenil Plus	Arthrum 75
Structure	Non-cross-linked	Non-cross-linked / weakly stabilised
Dose / volume	Example given: 20 mg / 2 ml	75 mg / 3 ml (approximately 2.5%)
Molecular weight	Described as standard	High-molecular-weight linear HA
Viscoelasticity	Described as standard	Mimics natural viscosity
Joint residence	Described as shorter; often multiple injections	Described as limited by the absence of cross-linking
Safety / chemistry	Conventional safety profile	Conventional safety profile
Positioning	Immediate tolerability	Conventional viscosupplementation

WHY CHOOSE HYARELIEF?

HYALURONIC ACID | KEY PRODUCT BENEFITS

Medicowl | group

Highly purified hyaluronic acid designed to support joint comfort and movement through intra-articular viscosupplementation.

JOINT LUBRICATION & CUSHIONING

Replenishes or replaces the viscoelastic properties of synovial fluid, supporting its natural lubricating and shock-absorbing role.

TARGETED SYMPTOM RELIEF

Intended for the treatment of symptoms of joint disorders such as osteoarthritis, including joint pain and stiffness.

A RANGE TO SUIT CLINICAL NEEDS

Seven linear strengths from 20 to 90 mg, plus the Cross formulations shown in this catalogue, allow the clinician to select the appropriate concentration and volume.

CROSS-LINKED FORMULATION

HyaRelief Cross uses a cross-linked hyaluronic acid gel designed to resist degradation. The supplied Cross brochure describes a single-injection treatment.

TREATMENT & PATIENT ASSESSMENT

HYARELIEF | INTRA-ARTICULAR VISCOSUPPLEMENTATION

Treatment schedule

The physician determines the number of injections and the treatment interval. The supplied brochure gives examples of 6, 8 or 12 months; follow the applicable instructions for use.

Known hypersensitivity

Do not administer to patients with known hypersensitivity to any product component or a history of such an allergy.

Infection at the injection site

Do not administer in the presence of a pre-existing skin infection near the intended injection site or an infection in the treated joint.

Systemic bleeding disorders

Do not administer in the presence of a known systemic bleeding disorder.

Bacterial protein sensitivity

The product may contain traces of Gram-positive bacterial proteins. Do not administer to patients with a history of allergy to these proteins.

Administration and repeat treatment require clinical assessment by a healthcare professional trained in intra-articular injection.